ImmunoPrecise Antibodies Ltd.
IPA
$3.20
$0.5721.67%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.91M | 4.33M | 4.49M | 3.84M | 4.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.91M | 4.33M | 4.49M | 3.84M | 4.76M |
| Cost of Revenue | 1.77M | 2.01M | 1.97M | 2.12M | 2.47M |
| Gross Profit | 3.14M | 2.32M | 2.52M | 1.72M | 2.29M |
| SG&A Expenses | 3.33M | 3.45M | 3.30M | 3.39M | 3.71M |
| Depreciation & Amortization | 74.60K | 438.40K | 449.00K | 442.60K | 516.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.95M | 6.64M | 6.57M | 7.16M | 7.62M |
| Operating Income | -1.04M | -2.31M | -2.08M | -3.31M | -2.86M |
| Income Before Tax | -1.34M | -17.26M | -2.24M | -3.49M | -13.87M |
| Income Tax Expenses | 183.60K | -2.12M | -370.60K | -566.70K | -894.70K |
| Earnings from Continuing Operations | -1.52M | -15.14M | -1.87M | -2.92M | -12.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.52M | -15.14M | -1.87M | -2.92M | -12.98M |
| EBIT | -1.04M | -2.31M | -2.08M | -3.31M | -2.86M |
| EBITDA | -765.50K | -1.69M | -1.42M | -2.66M | -2.20M |
| EPS Basic | -0.03 | -0.46 | -0.07 | -0.11 | -0.49 |
| Normalized Basic EPS | -0.02 | -0.04 | -0.05 | -0.08 | -0.07 |
| EPS Diluted | -0.03 | -0.46 | -0.07 | -0.11 | -0.49 |
| Normalized Diluted EPS | -0.02 | -0.04 | -0.05 | -0.08 | -0.07 |
| Average Basic Shares Outstanding | 45.80M | 32.85M | 28.13M | 27.13M | 26.65M |
| Average Diluted Shares Outstanding | 45.80M | 32.85M | 28.13M | 27.13M | 26.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |